UB Paderborn / Katalog / Suche / in CDI

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

The lancet oncology, 2016-07, Vol.17 (7), p.917-927

2016

Volltextzugriff (PDF)

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

Cancer research (Chicago, Ill.), 2011-07, Vol.71 (14), p.4758-4768

2011

Volltextzugriff (PDF)

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

Cancer discovery, 2012-03, Vol.2 (3), p.270-287

2012

Volltextzugriff (PDF)

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

PloS one, 2013-10, Vol.8 (10), p.e78881-e78881

2013

Volltextzugriff (PDF)

Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

Clinical cancer research, 2014-02, Vol.20 (3), p.617-630

2014

Volltextzugriff (PDF)

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

Neuro-oncology (Charlottesville, Va.), 2017-01, Vol.19 (1), p.89-98

2017

Volltextzugriff (PDF)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

BMC cancer, 2021-08, Vol.21 (1), p.1-904, Article 904

2021

Volltextzugriff (PDF)

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

Clinical cancer research, 2017-10, Vol.23 (19), p.5745-5756

2017

Volltextzugriff (PDF)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

BMC cancer, 2021-09, Vol.21 (1), p.1-1023, Article 1023

2021

Volltextzugriff (PDF)

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (10), p.1411-1418

2018

Volltextzugriff (PDF)

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

Journal of clinical oncology, 2018-02, Vol.36 (6), p.572-580

2018

Volltextzugriff (PDF)

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Journal of translational medicine, 2014-11, Vol.12 (1), p.294-294, Article 294

2014

Volltextzugriff (PDF)

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

Clinical cancer research, 2007-06, Vol.13 (12), p.3713-3723

2007

Volltextzugriff (PDF)

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors

Bioorganic & medicinal chemistry letters, 2012-08, Vol.22 (15), p.4979-4985

2012

Volltextzugriff (PDF)

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Cancer, 2016-12, Vol.122 (24), p.3856-3864

2016

Volltextzugriff (PDF)

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma

Clinical cancer research, 2023-10, Vol.29 (20), p.4186

2023

Volltextzugriff (PDF)

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations

Molecular cancer therapeutics, 2016-12, Vol.15 (12), p.2845-2852

2016

Volltextzugriff (PDF)

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

Neuro-oncology (Charlottesville, Va.), 2011-04, Vol.13 (4), p.384-392

2011

Volltextzugriff (PDF)

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

Journal of translational medicine, 2016-01, Vol.14 (12), p.12-12, Article 12

2016

Volltextzugriff (PDF)

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma

Clinical lung cancer, 2019-03, Vol.20 (2), p.74-81.e1

2019

Volltextzugriff (PDF)

Reply to C. Ren et al

Journal of clinical oncology, 2018-08, Vol.36 (22), p.2354-2356

2018

Volltextzugriff (PDF)

MET and VEGF: synergistic targets in castration-resistant prostate cancer

Clinical & translational oncology, 2011-10, Vol.13 (10), p.703-709

2011

Volltextzugriff (PDF)

Ras-Independent Transformation by v-Src

Proceedings of the National Academy of Sciences - PNAS, 1997-04, Vol.94 (7), p.3028-3033

1997

Volltextzugriff (PDF)

Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2063-2063

2023

Volltextzugriff (PDF)

Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.143-143

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–small-cell Lung Carcinoma

Reply to C. Ren et al

MET and VEGF: synergistic targets in castration-resistant prostate cancer

Ras-Independent Transformation by v-Src

Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma

Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer

Suchergebnisse filtern